Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III study of JS207 + JS007 versus toripalimab + bevacizumab as first-line treatment for advanced hepatocellular carcinoma
CTR20263532Phase 3Active
- Sponsor
- Shanghai Junshi Biosciences Co., Ltd.
- Start
- Sep 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of JS207, JS007, toripalimab, bevacizumab in hepatocellular carcinoma (HCC), sponsored by Shanghai Junshi Biosciences Co., Ltd.. Started Sep 2026; status: active.
02
Drugs
JS207JS007toripalimabbevacizumab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on CTR20263532.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20263532.